Accel Wealth Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Accel Wealth Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,500	Closed	-$540	–	936
2023 Q1	$540	Hold	1,500	–	–	﹤0.01%	1213
2022 Q4	$1.33K	Hold	1,500	–	–	﹤0.01%	940
2022 Q3	$2K	Hold	1,500	–	–	﹤0.01%	954
2022 Q2	$4K	Hold	1,500	–	–	﹤0.01%	846
2022 Q1	$3K	Hold	1,500	–	–	﹤0.01%	866
2021 Q4	$7K	Hold	1,500	–	–	﹤0.01%	774
2021 Q3	$11K	Hold	1,500	–	–	0.01%	630
2021 Q2	$15K	Hold	1,500	–	–	0.01%	617
2021 Q1	$12K	Sell	1,500 -7,375	-83%	-$77.9K	0.01%	630
2020 Q4	$61K	Buy	+8,875	New	+$71.3K	0.06%	266

Other funds holding SRNE

SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return

KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

OAJ

Ogorek Anthony Joseph Williamsville, New York $403M AUM 22.57% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

TCOV

Trust Company of Vermont Brattleboro, Vermont $2.68B AUM

CFGS

Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return

Accel Wealth Management's SRNE Position: Q2 2023 in Review

Accel Wealth Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 1,500 shares — an estimated $540 sold.

Accel Wealth Management first reported a position in SRNE in Q4 2020 and held it in 10 quarters. The position peaked at $61K in Q4 2020. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

Accel Wealth Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
Accel Wealth Management sold 1,500 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $540.
Accel Wealth Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2020 and held it in 10 quarters.
Accel Wealth Management's Sorrento Therapeutics, Inc. position peaked at $61K in Q4 2020.
9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on Accel Wealth Management's 13F filing for Q2 2023, filed 24 Jul 2023.